Overview

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous system (CNS). HSCT is the transplantation of stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Adienne SA
Dana-Farber Cancer Institute
Treatments:
Fludarabine
Fludarabine phosphate
Methotrexate
Thiotepa